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The management of articular cartilage lesions is one of the weighty challenges for orthopaedic 
surgeons. Gradual deterioration of articular cartilage from trauma or degenerative 
pathophysiology leads to swelling of the synovial joint, debilitating pain, functional 
impairment, and eventually osteoarthritis. Cell-based repair techniques have been extensively 
investigated in last few decades to improve the treatment regime for cartilage repair. The use 
of mesenchymal stem/stromal cells (MSCs) has demonstrated as an alternative cell source for 
cartilage repair due to their multilineage differentiation potential and hypoimmunogenic 
properties. Despite the advances in MSC-based cartilage repair techniques, there is no 
consensus relating to the most suitable cell type for cartilage repair or osteoarthritis treatment. 
The overall aim of this thesis was to investigate and compare the in vitro chondrogenic 
potential, and paracrine signalling potential of MSCs to find a suitable source for cartilage 
repair. Additionally, we also used efforts to gather new knowledge about cell-based biomarkers 
to predict clinical outcomes after cell transplantation procedures. 
In the paper I, we characterised and compared in vitro chondrogenic capacity of stromal cells 
harvested from Hoffa’s fat pad (HFPSCs), synovial membrane (SMSCs), umbilical cord 
(UCSCs) and articular cartilage. We demonstrated poorer in vitro chondrogenesis of MSCs 
from umbilical cord compared to cells harvested from adult joint tissues. The reason for poor 
chondrogenic capacity is yet to be elucidated. However, the study of TGF-β receptors revealed 
low expression of TGF-β receptor type II in umbilical cord stromal cells (UCSCs). This finding 
may explain the reason for poor chondrogenesis of UCSCs. In the paper II, we investigated the 
secretomes of HFPSCs, SMSCs, UCSCs and chondrocytes (ACs) to unveil in vitro secretory 
protein profiles that contribute to paracrine signalling and immunomodulatory characteristics. 
We found that UCSCs secretes less catabolic factors and less pro-inflammatory factors 
compared to cells from the adult origin. Considering the anti-inflammatory and pro-anabolic 
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paracrine effects of secreted soluble molecules, UCSCs could be used as an adjuvant therapy 
for cartilage repair.  
In the paper III, we investigated if in vitro chondrogenic potential of donor-matched surplus 
chondrocytes from Autologous Chondrocyte Implantation (ACI)-treated patients could predict 
clinical outcomes. Counterintuitive, we did not observe any correlation between in vitro 
chondrogenic capacity of cultured cells and short-term clinical outcomes. Additionally, 
constitutive expression of previously proposed and novel chondrogenic markers had no value 
to predict clinical outcomes. Of interest, high-throughput LC-MS/MS protein analysis revealed 
prolyl 4‑hydroxylase 1, an enzyme involved in collagen biosynthesis, as a novel biomarker 
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1.1 Articular cartilage 
Articular cartilage is a specialised connective tissue that covers the ends of bones of the 
diarthrodial joint. It is an aneural and avascular type tissue, which obtains nutrients by diffusion 
from the surrounding synovial fluid and the subchondral bone [1]. The primary function of 
articular cartilage is to provide frictionless movement of load bearing surfaces and to absorb 
and distribute the mechanical loading generated during locomotion. The thickness of juvenile 
articular cartilage is approximately 2.7-4 mm [2], while the thickness decreases in adult 
articular joints and it ranges between 2-2.5 mm [3, 4]. Articular cartilage is sparsely populated 
with cells called chondrocytes, which constitute approximately 2 % of total tissue volume [4]. 
The main bulk of the cartilage tissue volume comprises extracellular matrix made of collagen 
type II, proteoglycans and glycosaminoglycans (GAGs), which provides structural integrity and 
the capacity to retain water molecules.  
Mature cartilage contains primarily water, which makes up approximately 70-80 % of its weight 
[5]. Hyaline cartilage tissue is organised into four different zones from the articular surface 
down to the subchondral bone that facilitates its specific biological and mechanical functions 
(Fig. 1A). The superficial zone (also known as a tangential zone) lines the surface of articular 
cartilage and comprises 10-20 % of the tissue. It is characterised by densely packed collagen 
fibrils and flattened cells that oriented horizontally to the articular surface [6]. This zone has 
low proteoglycan content and low permeability that facilitates to handle the sheer forces during 
locomotion. However, chondrocytes produce lubricin (also known as proteoglycan 4) that 
serves as a lubricant and provides frictionless movement of knee joint [7]. It has been reported 
that superficial layer contains progenitor/stem cells that are responsible for appositional growth 
during development [8]. The middle zone or transitional zone is characterised by rounded cells 




Figure 1: Structure of human articular cartilage. A. The zonal organisation of articular 
cartilage showing the organisation of chondrocytes and collagen fibrils in a different layer. B. 
Regional organisation of articular cartilage showing chondrons and proximity of ECM from 
the chondrocytes. Scale bar: 10 µm. 
Unlike the superficial zone, this zone has more proteoglycan content and lower cell density. 
The deep or radial zone is rich in thick collagen fibrils oriented perpendicularly to the articular 
surface. In the deep zone, cells often group in columnar orientation along with collagen fibres. 
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A thin line below the deep zone called “the tidemark” distinguishes between the non-calcified 
and calcified zone. In this zone, cells are scarce and hypertrophic. The calcified zone serves as 
an anchor for the cartilage tissue that is fused with the underlying subchondral bone via the 
cement line [9].  
Based on the proximity of chondrocytes and surrounding extracellular matrix (ECM), cartilage 
can also be distinguished into several regions (Fig. 1B). The pericellular region is the immediate 
surrounding matrix of chondrocytes. The so-called “chondron” consists of chondrocytes and 
its pericellular region, which represents the simplest metabolic and functional structure of 
cartilage [10]. The area surrounding the pericellular matrix is termed as the territorial matrix. 
It is mainly composed of chondroitin sulphated proteoglycans and collagen type VI [11, 12]. 
The interterritorial matrix represents the bulk of ECM, which are most distant from the cells 
and contains mainly collagen type II and keratin sulphate-rich proteoglycans [13].              
In articular cartilage, there are two major load-bearing macromolecules: collagens and 
proteoglycans. The collagen serves as a scaffold and forms the ECM framework to withstand 
tensile forces during movement. Collagen type II is the predominant (~ 90 %) collagen type in 
the ECM matrix of articular cartilage. Collagen type IX and XI associate with collagen type II 
and mediate between collagen fibrils and other ECM macromolecules [14]. Other collagens 
such as collagen type VI contribute to the mechanical function of chondrons and maintain direct 
interaction between chondrocytes and ECM [15], while collagen type X mediates cartilage 
mineralisation [16]. The proteoglycan network consists of core protein and 
glycosaminoglycans (GAGs) that links to a long chain of hyaluronan molecule. This long chain 
interlaces throughout the collagen network and forms a large polymer chain with many 
proteoglycans (Fig. 2). Aggrecan is the most abundant proteoglycan and contains negatively 
charged chondroitin sulphate and keratan sulphate [17]. This strong negative charge causes the 
matrix to absorb water, which creates an osmotic pressure in the joint that equilibrates the 
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compressive loading forces. The avascular, alymphatic and aneural nature of cartilage is behind 
the low healing potential once the tissue is injured or diseased.      
 
Figure 2: Collagen network and proteoglycan polymer chain form ECM backbone of articular 
cartilage. 
1.2 Cartilage injuries and Osteoarthritis  
Forces transmitted at the knee joint during normal physiological activity range from 1.9 to 7.2 
times of body weight [18]. An imbalance between ECM mechanobiology and the loading forces 
transmitted across the joint can result in deterioration of the cartilage [19]. The primary causes 
of articular cartilage injuries are mechanical trauma or chronic degenerative diseases. Cartilage 
injuries caused by mechanical trauma can be classified into three types based on the kind of 
tissue damage [20]: chondral defects, osteochondral defects, and intra-articular fractures. 
Approximately 20 % of patients undergoing knee arthroscopy are reported to have chondral or 
osteochondral defects [21]. Like major knee traumas, repetitive microtraumas from sports 
activities could also lead to localised cartilage damage. These cartilage lesions if left untreated 
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may enlarge and contribute to the development of degenerative diseases. Progressive 
degeneration of knee cartilage leads to osteoarthritis (OA). It is the most common type of 
degenerative joint disease affecting globally over 250 million people and expected to be the 
fourth leading cause of disability by 2020 [22].  
 
Figure 3: Pathophysiology of osteoarthritis. A. Healthy articular cartilage and B. Signalling 
pathways and structural changes in osteoarthritis (reproduced with permission from [23]). 
OA is a multifactorial chronic disease of the whole synovial joint and is characterised by ECM 
degradation and impaired joint microenvironment due to maladaptive repair responses to 
cartilage injuries [24]. There are many risk factors identified for OA progressions, such as age, 
joint trauma, joint overload, obesity and inflammation, but the exact reasons of OA are still 
unknown [23]. Age is considered as the most influential risk factor for OA development [25], 
whereas traumatic knee injuries increase the risk of developing of OA by more than four times 
[26]. Early events during OA development are the activation of quiescent chondrocytes to form 
6 
 
clusters and increased non-aggregated proteoglycan, and collagen type I production [27, 28]. 
Initial tissue injury triggers the production of several inflammatory cytokines, such as IL-1β, 
IL-6, and TNF-α. As a consequence, articular cartilage degenerates by the acceleration of 
catabolic activities such as proteolysis of aggrecan by aggrecanases (ADAMTS 4 and 
ADAMTS 5) and degradation of collagen type II by matrix metalloproteinases (MM1, MMP3, 
and MMP13) (Fig. 3) [24, 29, 30]. As the OA progresses, water retention ability of articular 
cartilage decreases. Therefore, the resistance of knee cartilage to compression decreases and 
transmits mechanical loading towards the subchondral bone. Commonly used surgical and 
nonsurgical OA treatment modalities include intra-articular injections of soluble materials such 
as corticosteroids or hyaluronate, autologous blood products, joint realignment, nonsteroidal 
anti-inflammatory drugs (NSAIDs), weight loss, and joint replacement. These procedures 
improve OA symptoms to a certain degree but do not completely heal the progressive loss of 
joint functions [31]. 
1.3 Cartilage repair techniques 
Several cartilage repair techniques have been developed for the treatment of focal cartilage 
defects. The most frequently used methods are microfracture [32], mosaicplasty [33], and 
autologous chondrocyte implantation [34]. The ultimate aim of these techniques is to regenerate 
native-cartilage type tissue for symptomatic relief of pain and functional recovery of cartilage 
integrity. The choice of these treatments is dependent on the defect size and location, and the 
health of surrounding cartilage. However, these methods have limited application for treatment 
of OA joints. Pros and cons of most commonly used cartilage repair techniques are briefly 
discussed in the following section. 
1.3.1 Microfracture 
Microfracture is a bone marrow stimulation method for cartilage repair. This technique creates 
a network of the holes in the subchondral bone at the base of the injured cartilage that permits 
the access of bone marrow stem cells and growth factors to form a fibrin clot in the cartilage 
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lesions (Fig. 4) [32]. It is probably the most commonly used cartilage repair method given its 
minimal invasiveness, low cost and technical ease. However, the repaired tissue is in most cases 
fibrocartilage in nature containing collagen type I, which make it less durable compared to 
native cartilage [35]. Microfracture is not recommended to treat large defects, for elderly 
patients or diseased joints [36]. This technique has not been exclusively studied for OA 
treatment; however, few studies demonstrated worsen outcomes in patients with OA [37, 38]. 
A detailed description, application, and outcomes of microfracture are outside the scope of this 
thesis and discussed elsewhere [39].  
 
Figure 4: Illustration of microfracture technique. 
1.3.2 Mosaicplasty 
Mosaicplasty (osteochondral autograft transfer) involves harvesting healthy cartilage and bone 
plugs from a low-weight-bearing site of the joint and transplantation into the cartilage lesion 
[33]. This method is less associated with fibrocartilage formation and capitalises bone-to-bone 
recovery from patient’s joint (Fig. 5). The main advantage of this method is faster recovery 
potential than other methods due to graft stability [40]. This technique is best suited for smaller 
defects (≤ 4 cm2). It has been reported that patients treated with mosaicplasty had superior 
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athletic activity than patients treated with microfracture [41]. However, no significant 
differences in clinical outcomes are observed between mosaicplasty and microfracture after 
long-term follow-up [42]. The use of mosaicplasty in OA cartilage repair is rare, but it has been 
reported in patients with signs of OA [43].  
 
Figure 5: Illustration of the mosaicplasty procedure. 
1.3.3 Autologous chondrocyte implantation 
Autologous chondrocyte implantation (ACI) has been available as a method to ameliorate 
impairing localised cartilage defects since the early 90’s [34]. It is a two-step procedure using 
patient’s chondrocytes to treat the defect (Fig. 6). The first arthroscopic operation involves 
collecting a small biopsy from a low-weight-bearing region of joint and culturing the cells in 
vitro to increase cell yield. The culture-expanded chondrocytes are implanted into the debrided 
cartilage defect and covered with a membrane during the second operation. The first reported 
technique has experienced refinements such as the introduction of collagen membranes instead 
of periosteum to cover the defect (second generation ACI or ACI-C), the use of characterized 
chondrocytes to improve the quality of the repair tissue, or the so-called matrix-assisted 
chondrocyte implantation (MACI) where the chondrocytes are seeded in a collagen matrix 
before implantation (third generation ACI) [44, 45]. This technique has been demonstrated as 




Figure 6: Illustration of ACI procedure. 
The major drawback of this technique is the two-step operational procedure, high costs and the 
dedifferentiation (loss of function) of chondrocytes during the ex-vivo expansion phase. 
Implantation of dedifferentiated chondrocytes demonstrated to have worsened the outcomes of 
ACI [48]. Also, this method results in fibrocartilage formation, while only 15-30% of patients 
develop hyaline-like cartilage tissue [48, 49]. This technique is the least cost-effective surgical 
method compared to microfracture and mosaicplasty [50]. Although successful clinical 
outcomes have been reported for ACI, the long-term failure rate ranges between 20-40 % [47, 
51]. The use of this method is in degenerative cartilage lesions showed significant improvement 
in all scores in early OA patients treated with second-generation ACI [52]. Although a 
substantial improvement observed in the studied population, the number of failures was higher 
than what had been reported earlier in non-arthritic populations [53]. 
1.3.4 Other cell-based and cell-free cartilage repair approaches 
Considering the advantages and limitations of first and second generation of ACI, several cell-
based and cell-free methods have been developed for cartilage repair. The third generation ACI 
is scaffold-based cell therapy involving two operational steps. Chondrocytes are seeded on 
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absorbable porcine collagen membrane for three days (MACI) or chondrocytes are cultured 
inside the 3D scaffolds (Bioseed-C, NeoCart® 3D, Hyalograft® C, Cartipatch®, and Biocart™II) 
before implantation into the cartilage defects [54]. Although MACI had promising clinical 
results [55, 56], the problem with fibrocartilage tissue formation and longer rehabilitation time 
still exist [57, 58].  
 
Figure 7: Different cell-based and cell-free approaches to mimic ACI. A. Autologous bone 
marrow-MSCs implantation, B. Intra-articular injection of MSCs, C. AMIC, a cell-free 
scaffold-based surgery, D. MACI uses scaffolds with primary chondrocytes, E. Small 
particulated native cartilage approach and F. Scaffold-free chondrospheres or engineered 
neotissue (reproduced with permission from [59]). 
11 
 
Autologous matrix-induced chondrogenesis (AMIC) is single step procedure involving 
microfracture, to supply bone marrow stem cells and blood elements, and covering the defects 
with a collagen membrane (Fig. 7) [60]. The use of autologous serum or platelet-rich plasma, 
hyaluronic acid, and chitosan-glycerol phosphate with AMIC have emerged as a novel in situ 
approaches to treat cartilage lesions [61, 62]. No significant differences in short-term clinical 
outcomes have been observed between microfracture alone and in situ AMIC [63]. Unlike 
scaffold-based cell therapy, scaffold-free neotissue known as chondrosphere® has been 
developed to enhance cartilage regeneration [64]. It is composed of spheroids of neocartilage 
containing expanded chondrocytes and generated matrix. Chondrosphere® technique was 
reported to significantly improve the clinical scores after one-year follow-up [64]; however still 
lacking the long-term randomised control study. Other 3D scaffold-based chondrocyte therapies 
show some extent of improvement in the treated joints, but requiring the long-term randomised 
control clinical study. A detailed description and outcomes are reviewed elsewhere [54], which 
is outside the scope of the thesis. 
1.4 Alternative cell sources 
Autologous chondrocytes have been used as an intuitive cell source for cell-based therapy due 
to their direct implication in cartilage homeostasis. However, their use is limited to cell-based 
treatment by several issues, such as donor site morbidity, a limited number of cells that need 
expansion and the loss of phenotypic traits during monolayer expansion [65, 66]. Alternative 
cell sources have advantages over these commonly raised problems with chondrocytes. Cell 
sources that are being investigated in this field include embryonic stem cells (ESCs), adult 




Figure 8: Flowchart illustrating the hierarchy of stem cells.  
1.4.1 Mesenchymal stem/stromal cells (MSCs) 
MSCs are multipotent cell types with self-renewal and multi-lineage potential to differentiate 
into mesoderm cell types (Fig. 8). MSCs can be isolated from multiple tissues and organs 
including bone marrow, adipose tissue, synovial membrane, umbilical cord, muscle, and dental 
pulp [67-70]. These cells are heterogeneous cell populations with varying differentiation and 
proliferation potentials [70, 71]. Many scholars in the field support the notion that MSCs 
represent a defined population of multipotent progenitor cells residing in the perivascular niche 
of nearly all human tissues, [72, 73] although different views exist [74]. To improve the 
characterisation, The International Society of Cellular Therapy (ISCT) has set guidelines to 
define the traits of human MSCs [75]. These criteria are plastic adherence, expression of surface 
markers CD73 (ectonucleotidase), CD90 (thy-1) and CD105 (endoglin), and the ability to 
differentiate towards multiple cell types of mesenchyme origin, such as adipocytes, 
chondrocytes and osteocytes. In addition, to avoid contamination of MSCs from other cell 
types, these cells should not express hematopoietic and other immune cells markers such as 
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CD34, CD45, CD14, and CD19. MSCs do not express HLA-DR; however, priming of cells 
with inflammatory cytokines can induce expression of this receptor [76]. Bone marrow and 
adipose tissue MSCs are most frequently used for cartilage repair. In addition, patients treated 
with MSCs from synovial membrane reported having superior clinical outcomes compared to 
MACI [77]. Although MSCs are considered as a suitable alternative cell source, their 
proliferation and differentiation potential were reported to be affected by ageing [78, 79].  
 
Figure 9: Dissection of human umbilical cord showing Wharton’s jelly, cord lining, vein, and 
arteries (reproduced with permission from [80, 81]).  
1.4.2 Umbilical cord stem/stromal cells (UCSCs) 
To avoid aforementioned problems with adult MSCs, cells have been isolated from perinatal 
extraembryonic sources, such as umbilical cord, placenta, and amniotic fluid [80, 82]. 
Umbilical cord derives from the epiblast during embryonic stage; therefore, it retains some 
embryonic characteristics [83]. Umbilical cord stem/stromal cells (UCSCs) are immature and 
collected from what is considered as medical waste, which makes it easily accessible with 
minimal ethical constraints to use a suitable source of allogeneic MSCs. UCSCs can be isolated 
from different regions of the cord, such as Wharton’s jelly, vein, arteries, and cord lining. MSCs 
from different regions possess comparable proliferation and differentiation potential (Fig. 9) 
[80, 84]. In addition to MSCs from solid parts of cords, MSCs derived from cord blood have 
also been isolated and demonstrated to have the multi-lineage potential [85, 86]. Like adult 
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counterparts, UCSCs also possess high proliferative and multi-lineage differentiation potentials 
[80, 87]. In addition to these characteristics, UCSCs possess pro-angiogenic, anti-inflammatory 
and low immunogenic characteristics compared to other MSCs [88-90]. Low immunogenic 
properties of UCSCs allow these allogeneic cells to evade immune rejection after 
transplantation [91, 92]. However, their chondrogenic potential has been studied with divergent 
outcomes, such as immature cartilage forming, and poor chondrogenic ability compared to other 
cell types [70, 93-95].   
1.4.3 Embryonic stem cells 
ESCs are pluripotent and have the potential to differentiate into any type of cells in the adult 
body. ESCs are isolated from the blastocyst stage of embryos by removing the inner cell mass 
and subsequently, expanded in culture [96]. The outer cell layer known as trophectoderm forms 
the umbilical cord and placenta (Fig. 8). This pluripotent cell type has been demonstrated to 
differentiate into chondrogenic lineage [97]. However, due to the high risk of tumourigenicity, 
it is essential to growing ESCs in stable culture conditions for chondrogenic differentiation [98]. 
In addition to teratoma formation, ethical constraint limits the use of ESCs in clinical 
application.  
1.4.4 Induced pluripotent stem cells 
iPSCs are genetically reprogrammed stem cell types derived from any somatic adult cell type 
by transfecting cells with Oct3/4, Sox-2, Klf4 and c-Myc (Fig. 8) [99]. This technique provides 
new insight into cartilage repair by reprogramming cells into chondrogenic lineage [100]. iPSCs 
generated from chondrocytes demonstrated to have superior chondrogenic potential compared 
to iPSCs from other sources [101]. One of the major challenges involves incomplete 
reprogramming of iPSCs [102]. It has been reported that iPSCs retain epigenetic memory and 
genetic background [103, 104]. These characteristics cause the variation during reprogramming 
of iPSCs. In addition, there still other challenges that need to be addressed, such as safety, 
tumourigenicity, regulatory validation, and chondrogenic efficacy [105].  
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1.5 Cartilage Tissue-engineering  
Chondrogenesis is a complex process of cartilage development initiated by MSCs condensation 
during embryonic development. This condensation process is regulated by a series of cell-cell 
and cell-matrix interactions. During foetal development, cartilage serves as a template for bone 
formation and is subsequently replaced via endochondral ossification except for the end layer 
of bones [106, 107]. A detailed description of signalling pathways can be found elsewhere 
[108]. Appositional growth of articular surfaces continues until skeletal maturity [109]. 
Understanding the process of endochondral bone formation has played a pivotal role in the 
development of chondrogenic medium for tissue-engineered cartilage (TEC-here understood as 
laboratory made cartilage tissue). The development of artificial TEC encompasses several 
fundamental elements. These are cell sources, culture conditions, scaffolds, and 
biochemical/biomechanical stimuli. Although chondrocytes are considered as the intuitive 
source, MSCs, ESCs, and iPSCs are all demonstrated to be a suitable source for cartilage repair 
(Section 1.4). TEC using ACs and MSCs will be discussed in the following section due to 
relevance to this thesis.  
The scientific community has not reached a consensus on the ideal cell source for TEC. Bone 
marrow-derived MSCs have been considered as the gold standard. However, few noteworthy 
comparative studies showed SMSCs as a superior cell source for TEC (Table 1). The ability of 
cells to induce chondrogenesis is mostly dependent on the exogenous stimuli and signalling 
molecules. Important environmental elements considered in cartilage tissue engineering can be 
divided into two categories: 1) signalling molecules and factors that facilitate cell proliferation 
and expansion in monolayer and 2) signalling molecules or exogenous stimuli that facilitate 
chondrogenic differentiation in 3D culture to promote ECM production.  
1.5.1 2D culture phase (cell expansion) 
The serum is essential for monolayer expansion of cells to enhance proliferation [110, 111]. 
Although serum supplementation of media is most commonly used for ex-vivo culture 
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expansion, there is an argument on avoiding exogenous FBS. It has been shown to be affected 
by source and batch-to-batch composition. To avoid these issues, autologous serum or suitable 
anabolic factors, such as dexamethasone, and ITS have been used as media supplement for 
culture expansion of cells [112, 113]. Ascorbic acid, a water-soluble antioxidant, induces in 
vitro cell proliferation and collagenous matrix deposition upon addition to the culture medium 
[114, 115]. Monolayer culture of adherent cells is often supplemented with additional growth 
factors to promote cell proliferation. Among all growth factors, bFGF is the most commonly 
used anabolic factor in monolayer expansion of cells to promote proliferation, stem cell renewal 
and to keep the chondrogenic potential [116, 117].  However, varying concentration of bFGF 
might have a different effect on proliferation and matrix production [118].  
1.5.2 3D culture phase (matrix formation) 
In vitro expansion of chondrocytes in monolayer cultures leads to undesirable loss of function. 
This characteristic was first reported in the late 60’s by observing changes in cell morphology 
and reduction of chondroitin sulphate synthesis [119]. This fact promoted the development of 
culture systems that preserve the chondrogenic potential such as the pellet culture [120].  
Passaged cells are integrated into either a scaffold-based or a scaffold-free 3D construct to 
induce chondrogenesis. Scaffold-based 3D construct provides ECM niche for seeded cells to 
grow and differentiate into the scaffold to form TEC. Ideal characteristics of scaffolds are 
biocompatible, biodegradable, porous, and supportive for chondrogenesis [121, 122]. There are 
two main types of scaffolds used in cartilage tissue engineering: natural biopolymers and 
synthetic biopolymers. Natural scaffolds facilitate cellular adhesion, and synthetic scaffolds 
improve structural integrity. Poly L-lactic acid and polyglycolic acid are the most commonly 
used synthetic scaffolds in cartilage tissue engineering [123]. Commonly used natural scaffolds 




Table 1: List of some comparative studies analysing the chondrogenic potential of human 
MSCs from various sources. AC: Articular chondrocytes, AT: Adipose tissue, BM: Bone 
marrow, SM: Synovium, FP: Fat pad and UC: Umbilical cord. 















        SM  [126] 
        SM  [127, 
128] 
        AC>FP>BM>AT  [71] 
        Similar 
chondrogenesis 
[129] 
        AC>SM>FP>UC 
matrix  
[70] 
        SM  [130] 
        FP  [131] 
        FP>BM>AT>UC 
matrix. 
[132] 
        AC  [133] 
        Nasal septum  [134] 
        AT  [93] 
        AT and BM  [135] 
 
Scaffold-free 3D constructs have certain advantages over scaffold-based approaches for clinical 
applications. Scaffold-free 3D constructs do not involve complicated processing steps or toxic 
degradation, and it provides a natural microenvironment compared to scaffold-based 
approaches [136, 137]. It has also been reported to affect the morphology of chondrocytes due 
to crosslinking density of polyethyleneglycol scaffold [138]. Detailed techniques and 
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comparisons about scaffolds used for TEC can be found in some reviews [139, 140]. In 
scaffold-free approaches, cells are cultured in dense cell formations to facilitate TEC formation 
by cell-cell interactions [70, 141]. There are different techniques for preparing scaffold-free 
cartilage 3D construct. Cell aggregation and cell self-assembly are the most commonly used 
techniques for cartilage tissue engineering. Pellet culture is a cell aggregation method in which 
cells (0.5-2.5 x 105) are centrifuged in small well or tube to form small tissue-like structures 
under 1 mm in diameter (Fig. 10) whereas in self-assembly technique TEC is formed without 
applying any centrifugal forces.  
 
Figure 10: Schematic of pellet culture method for chondrogenesis. 
Supplementation of anabolic growth factors to promote chondrogenesis during 3D growth, is a 
normal practice to achieve TEC. TGF-β is the master regulator of chondrogenesis and ECM 
production in pellet culture [142]. The first well-established TGF-β chondrogenic medium in 
the 1990s still influences presently used chondrogenic medium [143]. Along with TGF-β 
supplementation, the chondrogenic medium is often enhanced by BMPs, PTHrP, ITS, 
dexamethasone, ascorbic acid, glucose, and pyruvate. However, it has been demonstrated that 
the presence of serum reduces ECM production during in vitro chondrogenesis [120]. ITS and 
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dexamethasone, on the other hand, have been shown to enhance chondrogenic differentiation 
and matrix production during 3D chondrogenesis [112, 144].  
The TGFβ superfamily includes the TGFβ and BMP subgroups and plays a central role in 
articular cartilage development and homeostasis. TGFβ subfamily acts by binding of receptor 
type II (TGFβRII) with ligand and activates receptor type I (TGFβRI, ALK1 or ALK5), which 
mediate SMAD signalling by phosphorylation. This signalling cascade is important during 
cartilage development. Ligand binding to ALK5 activates SMAD2/3 signalling while ALK1 
triggers the SMAD1/5/8 downstream cascade [145, 146]. TGFβRIII receptor enhances ligand 
binding for TGFβRII and TGFβRI. The ALK1 pathway becomes activated mostly with ageing 
and in OA cartilage compared to the ALK5 pathway that is active in healthy cartilage [147]. 
On the other hand, the BMP subfamily binds with BMPRII and activates BMPRIA (ALK1, 
ALK2 and ALK3) or BMPR1B (ALK6) to mediate downstream signalling by SMAD1/5/8. A 
detailed description of their pathway can be found in this review [148].  
BMPs are included in the chondrogenic medium to exert synergistic effects along with TGF-β 
[149, 150]. They also involve in promoting chondrogenesis, maturation of chondrocytes and 
terminal differentiation. To reverse hypertrophic phenotype, PTHrP is added to the 
chondrogenic medium [151]. Low glucose has been reported to be beneficial for 
chondrogenesis of culture-expanded chondrocytes [152]. In contrast, high-glucose was 
demonstrated to promote cells survival and proteoglycan synthesis in pellet culture [153], which 
was also observed in our studies [70]. In addition, hypoxia is another essential factor that 
provides microenvironment niche with low oxygen tension during 3D culture. It facilitates 
chondrogenesis and reduces apoptosis in the 3D culture [154]. However, static culture condition 
often results in poor ECM development. This leads to the development of bioreactors involving 
mechanical stimulation, such as compressive, shear, and hydrostatic forces, to mediate collagen 
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production and improve the orientation of collagen in TEC [155-157]. Following review is 
recommended for detailed description bioreactors and its mechanism [158].  
1.6 New concepts on MSCs regenerative potential 
The tissue regenerative potential of MSCs was thought to rely on the capacity of MSCs to 
migrate and engraft in damaged tissues, and transdifferentiating into tissue forming cells to 
promote tissue repair [159]. However, the fate of implanted cells during biological repair of 
cartilage is mostly unknown. The presence of cells of unknown origin in the repaired tissue has 
also been documented [160, 161]. Importantly, considering the effects of soluble signalling 
molecules from cultured MSCs, Arnold Caplan first proposed MSCs as trophic mediators in 
tissue regeneration [162]. This change of paradigm in understanding MSCs mechanism of 
action involves paracrine signalling and trophic effects exerted by the released bioactive 
molecules from MSCs, which in turn leads to support tissue microenvironment and 
reconstruction of the damaged tissue [163, 164]. Co-culture studies have demonstrated that 
MSCs facilitate proliferation and ECM enrichment of chondrocytes in a paracrine fashion, 
irrespective of sources of MSCs [165, 166]. A human clinical trial using allogeneic bone 
marrow MSCs demonstrated the trophic effects of this cell population during cartilage repair 
[167]. MSCs secrete a spectrum of bioactive soluble factors known as the secretome, 
comprising growth factors, cytokines, and chemokines that work in an omnidirectional way to 
regulate angiogenesis, apoptosis, and inflammation (Fig. 11). 
Inflammation during OA disease progression is prompted by resident cells in the synovial joints 
such as chondrocytes or synoviocytes [168, 169]. The bioactive molecules released by local 
tissue resident cells could have a pleiotropic effect at the disease site, which could trigger 
inflammatory cascades. Importantly, it has been demonstrated that MSCs secretomes may be 
influenced by inflammatory conditions at the damaged tissue [170, 171]. Therefore, for 
experimental purposes, pre-activation of MSCs with pro-inflammatory cytokines is often 
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considered to reveal immunosuppressive effects [172, 173]. However, it has also been 
demonstrated that non-activated MSCs also exert similar immunosuppressive effects [174]. Of 
note, ex vivo pre-activation of cells has been shown to cause immunogenic effects upon 
transplantation [175, 176]. Therefore, it is likely that MSCs undergo a phenotypic activation 
upon exposure to the inflammatory environment.  
 
Figure 11: Schematic of multifunctional effects of MSCs through bioactive soluble factors 
(reproduced with permission from [177]). 
Safety is the major concern when considering MSCs-based therapy for disease management. 
Like autologous MSCs, it has also been demonstrated that allogeneic MSCs are safe and 
promote immunosuppressive effects during cartilage repair (Table 2). Both autologous and 
allogeneic MSCs have shown similar efficacy in bone regeneration in a preclinical study [178]. 
Although it has become well established concerning the equivalent efficacy of autologous and 
allogeneic MSCs, there are controversies that evidently showing immunogenic responses after 
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allogeneic transplantation [176, 179]. Importantly, routes of administration may influence the 
therapeutic efficacy of MSCs. Allogeneic MSCs are currently administered via systemic route 
for the treatment of diseases such as graft-versus-host disease, Crohn’s disease, and respiratory 
disease in the clinical trials because of the immunosuppressive properties [180]. Systemic 
administration results in rapid clearance of MSCs, which decreases the number of MSCs 
delivered to the injured site [181]. It results in poor therapeutic effects of administered MSCs. 
In addition, it may raise the concern of losing immunomodulatory property and may initiate 
immune response [182]. Local administration of MSCs for cartilage repair, which is an 
immunoprivileged tissue, often avoids these complications. Intra-articular injection of MSCs in 
induced OA in preclinical models have shown that MSCs could inhibit OA progression [183, 
184]. Similar findings have also been reported in clinical studies (Table 2). However, there is 
still no evidence about the suitable source of MSCs or superiority MSCs over chondrocytes for 
cartilage repair or OA management. One comparative clinical study demonstrated the superior 
effect of MSCs from synovial membrane compared to chondrocytes in the treatment of chondral 
defects [77]. 
Table 2: List of few clinical studies using MSCs for articular cartilage repair and OA. AT: 
Adipose tissue, BM: Bone marrow, FP: Fat pad, HA: Hyaluronic acid, IA: Intra-articular, 
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1.7 Biomarkers for cartilage repair 
Although ACI has been clinically adopted for cartilage repair since the 1990s, the procedure 
has a long-term failure rate ranging between 20-40 % [47, 51]. Some patient characteristics 
including demographic and injury-associated risk factors have been identified [198-200]. Along 
with these risk factors, Osteoarthritis Research Society International (OARSI) highlighted the 
importance of identifying soluble biomarkers to predict the clinical outcome before ACI 
intervention and to improve the decision-making process for patients with cartilage injuries 
24 
 
[201]. The investigation of biomarkers can be broadly divided into two source types: 1) liquid 
biopsies including synovial fluid, blood and urine and 2) cell quality (Table 3). Few putative 
biomarkers, such as CD14, and ADAMTS-4, have been identified from synovial fluids [202-
204].  
Acknowledged markers of chondrogenesis including cell adhesion molecules, integrins, 
chondrogenic signalling pathways and matrix proteins have been explored to find suitable cell-
based biomarkers with predictive potential in the clinics. Cell adhesion molecules and cell-cell 
contact receptors play a pivotal role in initial cell condensation and differentiation during 
chondrogenesis. Previously proposed chondrogenic biomarkers include surface receptors such 
as CD44, CD151, CD146, FGFR, CD29 or CD49.  CD44 (Hyaluronan receptor) plays a crucial 
role in cartilage homeostasis and structural orientation of pericellular matrix by retaining 
aggrecan aggregates [205, 206]. Also, CD44 has been reported to positively correlate with 
chondrogenesis and short-term clinical outcome [207, 208]. Like the CD44 marker, CD146 
(melanoma cell adhesion molecule/MCAM), CD151 (tetraspanin) and CD166 (activated 
leukocyte cell adhesion molecule/ALCAM) are also associated with enhanced chondrogenic 
potential [207] [209]. On the other hand, CD54 (intercellular cell adhesion molecule 1/ICAM-
1) has shown a divergent outcome when comparing chondrogenic potentials in different stem 
cells [210, 211].  
Like cell adhesion molecules, integrins are also known for their effects on cartilage 
homeostasis. Integrins are small molecule heteromeric cell-surface receptors that mediate 
cytoplasmic kinase and cytoskeleton signalling cascades in response to different stimuli, 
mechanical load, and differentiation. Change in cartilage homeostasis affects their expression 
and vice versa. The expression of all alpha subunits and the beta-1 subunit increase in OA 
chondrocytes [212, 213]. Therefore, change in the expression of integrins is considered an 
important regulator in cartilage repair. Integrins such as ITGA3 (CD49c), ITGA5 (CD49e), and 
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ITGA6 (CD49f) have been linked to improved chondrogenesis [207], while ITGB1 (CD29) has 
been associated with the inhibition of early chondrogenesis [214]. Although cell adhesion 
molecules, integrins, and cell-cell receptors have been considered as potential key players in 
chondrogenesis, the relevance of their expression in clinical outcomes is still questionable [215, 
216].  
Table 3: List of some human studies investigating biomarkers to forecast either 
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2 Aims of the thesis 
The aims of the work presented in this thesis were twofold: I) to study in vitro properties of 
mesenchymal stromal cells in search of the most suitable cell source for cartilage repair and II) 
to explore if the in vitro chondrogenic potency of cells used for ACI could predict clinical 
outcomes. 
The specific goals related to each presented work were: 
1. To characterise and compare the in vitro chondrogenic capacity of culture-expanded cells 
harvested from articular cartilage, synovial membrane, Hoffa’s fat pad and umbilical cord 
matrix. 
2. To characterise the secretory protein profiles of culture-expanded cells harvested from 
articular cartilage, synovial membrane, Hoffa’s fat pad and umbilical cord matrix, and to 
compare the immunoregulatory potential of the different cell secretomes.  
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3. To investigate if the in vitro chondrogenic capacity of patient-matched chondrocytes from 
ACI procedures could predict clinical outcomes. Additionally, to search if molecular 
biomarkers of chondrogenesis from cells could predict clinical outcomes.  
3 Methodological considerations 
In this section, I will briefly discuss strengths and limitations of some of the methodology 
included in this thesis.  
3.1 Biological material 
Regional Ethical Committee (REK Nord) evaluated and approved the research project. In 
papers I and II, articular cartilage as well as pieces of synovium and infrapatellar fat pad were 
collected from patients undergoing total knee replacements. Umbilical cords were collected 
during normal (non-cesarean) child-deliveries. Although we collected cartilage tissue from a 
macroscopically healthy looking area of the knee joints, the tissue source should be regarded 
as diseased tissue due to the general joint disease prompting a knee joint replacement. However, 
it has been demonstrated that chondrocytes from OA cartilage possess similar properties 
compared to cells from healthy donors when used for tissue-engineered cartilage [219]. In paper 
III, we used leftover chondrocytes from patients undergoing ACI, diagnosed with focal cartilage 
lesions but not OA. 
3.2 Cell isolation  
We used a mixed enzymatic-explant method to isolate cells from the tissue biopsy as described 
in the materials and methods of each paper. This approach increases the number of viable cells 
quickly in the culture flask compared to explant culture [220]. The tissue biopsies were minced 
and digested with collagenase XI. For cartilage, we used 3 h of digestion followed by washing 
and plating partially digested tissue for outgrowth culture (Fig. 12). For Hoffa’s fat pad, 
synovium membrane and umbilical cord matrix digestion period was only 1 h. We decided to 
minimise the exposure of collagenase to avoid any detrimental effects on quantity and quality 
of cells isolating from Hoffa’s fat pad, synovium and umbilical cord [221]. However, we needed 
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at least 3 h digestion in collagenase to reach the recommended 90% digestion of cartilage 
biopsies.  
 
Figure 12: Schematic of cell isolation process. Scale bar: 5 µm.  
3.2.1 3D cultures 
The 3D culture was carried out using a scaffold-free pellet culture and hanging-drop culture 
approach in our laboratory. We used this approach to facilitate TEC formation by aggregation 
and cell-cell interactions, providing biomimetic microenvironment compared to scaffold-based 
approaches such as alginate, agarose, and collagen. The scaffold-free approach also avoids 
complicated processing steps, and interferences that may arise between degradation of 
biomaterials and cells own matrix formation [136, 138]. We used both methods in paper III but 
used only pellet culture system in paper I. During our pilot experiments we found that the pellet 
culture was more easily reproducible and less time consuming than the hanging-drop method 
(Fig. 13). Spheroids prepared by hanging-drops were unsuccessful in a higher number of 
donors. The pellet culture is the most commonly used 3D culture method since the 1980s to 
induce chondrogenesis [120]. We used quite some efforts at the beginning to find the optimal 




Figure 13: Comparison of spheroids prepared by pellet culture and hanging-drop culture from 
same chondrocyte donor. Scale bar: 200 µm. 
 
Figure 14: Metachromatic staining (Alcian blue) of spheroids in the presence of only TGF-β1 
and combination of TGF-β1 and BMP-2. Scale bar: 200 µm. 
3.2.2 Serum  
We used the FBS-supplemented medium for expansion of cells in monolayers. The use of FBS 
is associated with the possible risk of contamination and may vary from batch to batch 
production. On the other hand, the use of human serum or platelet products avoid the risks 
associated with animal serum [222]. In addition, human serum or platelet products have been 
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demonstrated to enhance proliferation of cultured cells compared to FBS. However, expansion 
of cells monolayer in the presence of FBS and human serum has shown no differences when 
comparing differentiation potential [222, 223]. In 3D culture, we used a serum-free medium to 
induce chondrogenesis. To compensate for serum deficiency during chondrogenesis, we 
enriched the medium with ITS and dexamethasone. These anabolic factors have been shown to 
successfully promote chondrogenesis in the absence of serum [112, 144]. Additionally, in paper 
II, proteomics and multiplex protein assays were performed with the same serum-free 
conditioned medium (CM), which allowed us to make direct comparisons of results. However, 
functional assays with immune cells were done with serum-supplemented CM, as serum 
deprivation has been shown to affect proliferation and induce apoptosis in lymphocytes and 
macrophages, respectively [224, 225]. Short periods of serum deprivation have not affected the 
cell viability in previous studies [226]. We have analysed in parallel the expression of TNF-α, 
IFN-γ, IL-6 and IL-12 in both serum-containing and serum-free CM from all four cell types and 
only the expression of IL-6 was considerably changed in the presence of serum (Fig. 8 of paper 
II). Although we expect only minor phenotypic changes in cells associated with serum presence, 
alterations in the expression of some bioactive molecules could occur and should be taken into 
consideration. 
3.2.3 Glucose  
In the paper I and III, basal DMEM medium containing high glucose was used for 
chondrogenesis. During pilot experiments, we found spheroids prepared in high glucose 
chondrogenic medium had improved spheroid morphology and enhanced matrix production 
compared to low glucose chondrogenic medium (Fig. 15). Similar findings were observed by 




Figure 15: Comparison of spheroids from SMSCs from the same donor prepared in high 
glucose chondrogenic medium and low glucose chondrogenic medium. Scale bar: 500 µm. 
3.3 Flow cytometry 
Flow cytometry, a laser-based fluidics platform, is based on the principle of light scattering 
from individual particles in the liquid suspension. After hydrodynamic focusing of single cell 
suspension into a stream of fluid, each particle or cell in the suspension passes through the beam 
of a laser. The emitted light in the forward direction from the passing cells provides information 
about the size of the cells whereas the side scattered light gives information about complexity 
or granularity. The use of fluorescent conjugated-antibodies or dyes makes it a powerful tool, 
which provides a quantitative measure of the cell proliferation, enzyme activity, drug uptake, 
intracellular proteins, and surface proteins [227]. We employed this technique to analyse the 
surface marker expression of the protein of interests in the studied cell types. Flow cytometry 
is sophisticated and required multiple controls for analysis [228]. To determine cellular 
autofluorescence and set negative gates in the analysed cell population, we used antibody-free 
controls. On the other hand, isotype controls were used to check non-specific binding of 
antibodies. However, the use of isotype control is controversial when it uses as gating control. 
This is because the isotype control does not contain similar fluorescence-to-protein ratio as the 
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antibody. Fluorescence minus one (FMO) fluorophore control is considered as the suitable 
approach for multicolour complex immunophenotyping. In a multicolour assay, it shows how 
fluorophore spread over other channels while comparing with others, therefore allows setting 
right gate accordingly [228, 229]. Another approach involves compensating spectral overlap in 
multicolour flow cytometry by counting 5000 events in both positive and negative cell 
population. We used this approach to avoid fluorescence spill over in multicolour flow 
cytometry in the paper I. 
3.4 Real-time quantitative polymerase chain reaction 
Quantitative PCR (qPCR) is one of the widely used tools for quantification of RNA in a 
biological sample due to its robustness and specificity. RNA extraction is the first step of the 
process, which was important for us due to different sample types. In the paper I, we extracted 
RNA from both monolayer culture and tissue-engineered cartilage, whereas we only extracted 
RNA from monolayer culture in paper III. Extracting RNA from monolayer is straightforward 
and does not involve additional step. It is more challenging to extract RNA from spheroids. We 
collected few spheroids in an Eppendorf tube containing a stainless steel ball (5 mm) and 
disrupted the constructs in a TissueLyser for 2.5 min at 25 Hz. We used QIAshredder columns 
to homogenise and clean the RNA extract from spheroids [230]. To avoid DNA contamination, 
we performed on-column DNase digestion of the samples. A dye is incorporated in the qPCR 
reaction that results in the emission of fluorescence as cDNA doubled during each cycle. 
Therefore, fluorescence increase exponentially, which is detected by qPCR platform and the 
reaction can be monitored in real-time. The qPCR reaction slows down as reagents get limited 
followed by entering the plateau phase.  
The amount of cDNA produced during reverse transcription reflects the quality of starting RNA 
material [231]. Contaminants in the sample will also be exponentially amplified during the 
qPCR reaction. In addition, using too much RNA input in reverse transcription phase often left 
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out RNA that are not being reverse transcribed. These can be controlled by a series of dilution 
of RNA [231]. Therefore, we performed validation experiments with a five-step 1:10 dilution 
series to avoid such contaminations. Each dilution contained cDNA reverse transcribed in the 
presence of probes with both high expressing genes and low expressing genes. Results from 
validation experiments confirmed the efficiency of dilution curves within 90-110 % as 
recommended when excluding the undiluted samples. In addition, interpretation of qPCR 
results is based on the normalisation of expression of internal reference known as a reference 
gene. Therefore, it is important to include a reference gene that has a constant expression in all 
the studied samples [232]. We performed validation experiments with potential reference genes 
to find a suitable one with constant expression in our study. In the paper I, we found that 
YWHAZ was the stable reference gene while studying cartilage signature genes expression in 
3D culture. For the monolayer cultures studied in Paper III, RPL13A proved to be the more 
stable reference gene. 
 
Figure 16: Comparison of VCAN expression using a linear scale, log scale and dCq in 3D 
culture. 
Fold change of expression of target gene compared to control gene is a commonly used method 
to present the qPCR data. In the paper I, we used fold change to present our qPCR data. It was 
calculated from 2ddCq formula in which ddCq= Mean (dCq treated) – Mean (dCq control). 
However, the major drawback of using fold change as it shows upregulation nicely with positive 
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value but downregulation restricts between 1 and 0, which is unequally weighted the 
visualisation of results on a linear scale (Fig. 16). Therefore, we transformed y-axis to log scale 
in the paper I, which eliminates the problem of the unequal weight of up-and downregulation 
(Fig. 16). The use of dCq to represent qPCR data eases the interpretation of result and avoids 
the complications of using fold change and log scale [233, 234]. It is calculated by subtracting 
the Cq value of gene of interest from the Cq value of reference gene (dCq= Cq reference gene 
– Cq gene of interest). This method is straightforward and represents result with higher values 
as a higher expression of the gene of interest and vice versa (Fig. 16). We employed this 
technique to interpret qPCR data in paper II.  
3.5 Histological evaluation of spheroids 
We performed metachromatic staining of proteoglycan contents of spheroids to evaluate the 
chondrogenic potential of different cell types. The Bern score, a visual histological grading 
system, was used for semi-quantitative assessment of cartilage tissue constructs [235]. This 
method uses three categories that include the intensity of proteoglycans staining, cell and matrix 
density and morphology of cells in the tissue construct. One of the major limitations of this 
grading system is not including collagen content for evaluation of chondrogenesis. Therefore, 
the quality of tissue-engineered cartilage often misinterpreted while only using this scale. The 
inclusion of collagen content could solve this discrepancy. This discrepancy has been 
demonstrated in a study by our group in which we included the score for collagen contents 
using second harmonic generation microscopy [236]. We also proposed a further modification 
of this grading based on specific collagen type I and type II contents in engineered cartilage.  
In the paper I, we performed immunohistochemistry to compare expression and distribution of 
collagen type I and II in spheroids. We used formalin fixed 4 µm sections of spheroids that 
were prepared through series of ethanol washing, antigen retrieval, blocking of unspecific 
binding, peroxidase quenching before incubating with primary antibody. Antigen retrieval was 
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carried out using the enzyme-based method, which provided better antigen recovery than heat-
induced antigen recovery. Using later method, the sections were destroyed and resulted in poor 
antigen recovery. We performed validation experiments with cartilage and tendon as positive 
and negative control respectively, to determine the suitable dilution factor for antibodies. 
Validation studies confirmed that a dilution of 1:500 of collagen type I and 1:100 of collagen 
type II antibodies was suitable for our tissue-engineered cartilage.  
3.6 Proteomics 
Liquid chromatography coupled tandem mass spectrometry (LC-MS/MS) has emerged as a 
comprehensive tool for characterisation of protein profiles in a high-throughput manner. 
Quantitative mass spectrometry can be divided into two broad categories: label-free 
quantification methods and label-based quantification method [237]. Different label-based 
methods including metabolic labelling, chemical labelling, and enzymatic labelling have been 
developed to improve the quantification of proteins [238]. We performed ‘shotgun’ proteomics 
in which the whole proteome was digested without prior separation of proteins. Protein 
separation using gel electrophoresis is often associated with restricted sample throughput, and 
limited quantifiable proteins in a gel [237, 239].  
In the paper III, we used 6-plex tandem mass tag (TMT) based chemical labelling technique to 
look for differentially expressed proteins between samples with extreme scores. Unlike 
metabolic labelling (SILAC), TMT allows multiplexing of several samples in a single LC-
MS/MS run (Fig. 17). It has also been reported to provide more precise and reproducible 
quantification of peptides compared to metabolic labelling [238]. Each TMT tag in 6-plex 
contains a specific reporter ion of m/z 126, 127, 128, 129, 130 and 131, which can tag six 
different samples [240]. The relative intensities of each reporter ion are used to generate 
quantitative information of labelled peptides among different samples. In our studied materials, 
six samples with highest and lowest scores (3 in each group) were tagged with six different 
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reporter ions to derive quantitative information of differentially expressed proteins between two 
groups (Fig. 17).  
 
Figure 17: Schematic of different label-based and label-free protein quantification methods 
(Adapted with permission from [241]).  
Although label-based quantification provides data reproducibility, one of the major limitations 
of this technique is a restricted number of samples for analysis. It also requires complex sample 
preparation steps. Label-free protein quantification, on the other hand, is not restricted to a 
number of samples to be analysed. It is cost-efficient and involves simple sample preparation 
steps. In paper II, we analysed 16 samples using label-free protein quantification which allowed 
comparison of protein expression among four different sample types. TMT analysis does not 
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offer such flexibility of data analysis in a large number of samples. In addition, the label-free 
technique has been reported to provide broader proteome coverage and increased number of 
identified proteins [237]. However, each sample needs to be run separately in label-free 
quantification (Fig. 17). This data-dependent acquisition has been reported to associate with 
low reproducibility and to bias to picking the strongest signal for fragmentation, which could 
affect the analysis of low-abundance peptides. This approach could overcome by implementing 
data-independent acquisition in which all peptides are fragmented and not limited to the 
predefined peptides of interest [242]. In this thesis, our collaborator at the proteomics platform 
performed part of experimental procedures and proteomics data acquisition.  
3.7 Multiplex protein array 
We performed multiplex protein array in paper III to complement our findings from LC-
MS/MS. Some relevant cytokines, enzymes and growth factors may be expressed at a very low 
concentration in culture supernatants, which might fall below the detection limit by mass 
spectrometric analysis [243]. This antibody-based detection technique allows quantitative 
measurement of pre-determined proteins (up to 100) simultaneously from a small volume of 
sample. The antibody against the protein of interest is incorporated with beads with defined 
colour intensities, which binds with the respective protein in the sample and finally, detected 
by the fluorescent-conjugated detector antibody. One laser detects the protein of interest (colour 
of beads) and the second laser determines the fluorescence intensity, which is proportional to 
the bound protein of interest. It has been reported to have a similar sensibility and 
reproducibility like ELISA, but unlike ELISA, it is simple and less time consuming [244]. 
However, the quality of assays may vary from different suppliers [245]. Comparative analysis 
of our findings from LC-MS/MS and multiplex protein array confirmed the reproducibility of 




ELISA is the “gold standard” for quantitative measurement of proteins. However, it allows 
measuring only one protein at the time. It has the similar principle like multiplex protein array 
but differs in the detection system. It uses streptavidin-HRP-conjugate that binds to detection 
antibody and results in colourimetric detection of a protein of interest. We used this technique 
to check the concentration of targeted cytokine of interest, which was not included in the 
multiplex protein array. We did not encounter any problem while measuring the concentration 
of cytokines in our studied samples. However, we ran a few samples several times, such as 
TGF-β1, IL-6, and TNF-α to adjust the dilution factor. For TGF-β1 analysis, we diluted our 
samples as supplier’s instruction but failed to detect TGF-β1 in the supernatants of all other cell 
types except UCSCs. The concentration was below the detection limit, and we performed the 
analysis without any dilution and detected TGF-β1 in all cell types. 
3.9 Functional assay of immune cells 
We performed functional assays of immune cells in paper II. To perform these assays, we 
isolated PBMCs from whole blood of healthy donors. 
3.9.1 Lymphocytes proliferation assay 
 
 
Figure 18: Activation of lymphocytes with different concentration of PHA.  
We analysed lymphocytes proliferation using carboxyfluorescein succinimidyl ester (CFSE) 
dye dilution assay in paper II. CFSE, a membrane-permeable dye, covalently binds with 
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intracellular molecules. During cell division, CFSE also divides equally between daughter cells. 
A flow cytometer was used to analyse the CFSE labelled cells to measure the proliferation of 
lymphocytes. We used phytohemagglutinin (PHA), a widely used lymphocytic mitogen to 
activate lymphocytes. In our previous studies, we used 1 µg/mL of PHA to activate 
lymphocytes [246]. Surprisingly, we did not manage to achieve any activation using this 
concentration with a new batch of PHA. After a few pilot experiments with the new batch of 
PHA, we found that 10 µg/mL of PHA was the necessary concentration to activate lymphocytes 
(Fig. 18). At this concentration, no cell death was observed. In our study, we did not perform 
CD3+/CD4+ marker characterisation of T-lymphocytes. However, most gated cells correspond 
to CD4+ and CD8+ cells as demonstrated by us in earlier studies [246]. Both characterised, and 
non-characterised lymphocytes had similar proliferation pattern, and presence of B cells (<10 
%) did not interfere with the proliferation assay.    
3.9.2 Macrophage polarisation assay 
In the paper II, we checked for macrophage activation to investigate the immunomodulatory 
effect of culture supernatants from different cell types. We isolated CD14+ monocytes from 
PBMCs using magnetic-activated cell sorting. We incubated CD14+ monocytes with M-CSF 
for 6 d to induce macrophage differentiation (M0) (Fig. 19). M0 macrophages were then 
polarised into M1 and M2 phenotypes using LPS and IFN-γ and dexamethasone, respectively 
[247]. The detailed experimental procedure is written in paper II. We used dexamethasone 
induced M2 polarisation as a control to compare surface expression of a few costimulatory 
molecules with M1 polarised macrophages. We found discrepancies while going through 
literature regarding activation and phenotype changes of macrophages. To address a few of the 
issues, we performed several pilot experiments to decide on surface markers to include in the 
paper II. During our pilot experiments, we observed differential expression of co-stimulatory 
molecules among different cell types and stimulants used to induce polarisation. IL-10 usually 
studied as a marker for M2 polarised macrophages [248]. In our pilot study, we found that LPS 
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and IFN-γ stimulation increased the production of IL-10 compared to dexamethasone or TGF-
β and IL-4 stimulation. Previous studies also have shown these type of discrepancies [249-251].  
IL-10 has also been reported as an irrelevant marker for M2 polarised macrophages [247]. After 
pilot experiments, we decided not to include this as a marker for M2 polarised macrophages.  
 
Figure 19: Illustration of macrophage polarisation assay. 
In addition, CD206 is included as a marker for M2 polarised macrophages. We found CD206 
expression did not discriminate between M1 and M2 polarised macrophages in our pilot 
experiments using LPS and IFN-γ and dexamethasone, respectively (Fig. 20). Similar findings 
have been reported in an earlier study using an IL-4 stimulant for M2 polarised macrophages 
[248]. On the other hand, we found that CD163 was a suitable marker to discriminate between 
M1 and M2 polarised macrophages in our studied populations (Fig. 20), which has also been 
demonstrated in a previous study [247]. In our pilot experiments, CD206 expression was found 
to be a suitable marker to discriminate between M1 and M2 polarised macrophages when 
stimulated with TGF-β1 and IL-4 (Fig. 20). Since we used dexamethasone to induce M2 




Figure 20: Surface marker expression of CD163 and CD206 in non-polarised and polarised 
macrophages in the presence of different stimulants.  
4 Summary of results 
4.1 Paper I 
In this study, we isolated and characterised mesenchymal stromal cells from Hoffa’s fat pad, 
synovial membrane, and umbilical cord with the aim of comparing the in vitro chondrogenic 
capacity of culture-expanded cells. We also isolated chondrocytes from cartilage to use them 
as the gold standard. Cells from all sources maintained fibroblast-like and plastic adherent 
characteristics. UCSCs had a slow growth rate after initial plating compared to HFPSCs and 
SMSCs. However, the proliferation rate of UCSCs increased after first sub-culturing with 
homogeneous morphology. Unlike MSCs, chondrocytes had poor proliferation rate. All MSCs, 
including chondrocytes, were positive for classical surface markers such as CD73, CD90 and 
CD105, but did not express any haematopoietic, macrophage or endothelial markers. MSCs 
were also checked for expression of previously proposed markers of chondrogenesis including 
CD44, CD146, CD166, and CD271. None of the MSCs or ACs was positive for CD106 and 
CD271. We did not observe any differences in surface expression of CD44 or CD166 and only 
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a subtle change in expression of CD146. Additionally, we found no correlation between any 
surface markers expression and chondrogenesis.  
When studying in vitro chondrogenic potential by metachromatic staining of proteoglycan, we 
found that ACs underwent chondrogenesis in all six studied growth factor combinations. 
UCSCs, on the other hand, displayed poor chondrogenesis in all studied combinations. HFPSCs 
and SMSCs displayed the best chondrogenesis in the presence of TGF-β3 and BMP-2 
combination and TGF-β1 and BMP-2 combination, respectively. These findings were also 
reproducible at collagen level. When investigating cartilage signature genes expression in 
spheroids, we found significant downregulation of COL2A1, ACAN and SOX-9 in UCSCs 
compared to ACs. The relative expression of VCAN was significantly upregulated in spheroids 
from HFPSCs. To induce chondrogenesis in UCSCs, we performed co-culture of spheroids with 
cartilage pieces or cultured synoviocytes. However, we did not manage to induce proper 
chondrogenesis of UCSCs in these conditions.  
To investigate whether UCSCs remained undifferentiated in 3D culture, we studied stemness-
related transcriptional factors (SRTF). The results confirmed that UCSCs did not express any 
SRTF genes in 3D spheroids whereas they maintained the expression of these genes in 
monolayer culture. This supported that UCSCs underwent transition towards a differentiated 
state, which certainly was not cartilage type. Importantly, after publication, we investigated 
receptors from TGF-β superfamily in all cell types during the expansion phase. We found both 
TGFβRII and TGFβRIII were significantly downregulated in UCSCs compared to other cell 




Figure 21: Relative expression of receptors from TGF-β superfamily in different cell types 
before inducing chondrogenesis. Level of significance, * and ** with p-value < 0.05 and 
<0.005, respectively.  
4.2 Paper II 
In this paper, we studied and compared the secretory profiles of ACs, HFPSCs, SMSCs, and 
UCSCs from four unrelated donors using label-free LC-MS/MS. While comparing the protein 
profiles of each donor, the samples distributed in two major clustering; one cluster 
corresponding to the four donors of UCSCs and other cluster contained rest of the donors from 
adult cell sources. Qualitative comparisons of identified proteins showed that ACs (709) 
secreted more proteins in the culture medium compared to HFPSCs (641), SMSCs (567) and 
UCSCs (653). Among these identified proteins, 472 proteins were present in the supernatants 
of all cell types. UCSCs had more uniquely expressed proteins (50) than other cell types. In 
quantitative analyses, we found that cell signalling proteins such as TGF-β1, PDGFD, and 
MCP-1 were significantly upregulated in UCSCs, whereas catabolic proteins such as MMPs, 
serpins, and complement factors were downregulated compared to cells from the adult origin. 
Determination of growth factors and MMPs using multiplex protein arrays also confirmed the 
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findings from LC-MS/MS. When analysing results from multiplex protein arrays, we observed 
significant downregulation of MMP3 and MMP7 production by UCSCs compared to ACs. The 
concentration of TGF-β1 and PGE2, on the other hand, was significantly elevated in the 
supernatants of UCSCs compared to HFPSCs.   
To elucidate the immunosuppressive effect of supernatants from the different cell sources, we 
performed lymphocytes proliferation assays. We observed that UCSCs significantly blocked 
the proliferation of PHA-activated lymphocytes compared to other cell types. Additionally, the 
production of inflammatory cytokines TNF-α and IFN-γ by lymphocytes was only suppressed 
by UCSC supernatants. When comparing results from M1 polarised macrophages, we found 
that surface expression of different co-stimulatory molecules varied distinctly upon incubation 
of M1 polarised macrophages with supernatants from different cell types. Supernatants from all 
stromal cell types reduced surface expression of HLA-DR on activated macrophages. When 
comparing inflammatory cytokines productions by M1 polarised macrophages, we found that 
supernatants from all cell types suppressed the production of TNF-α, IL-6, and IL-12. 
Importantly, among all cell types, only UCSCs significantly reduced the production of IL-6 and 
IL-12 by M1 polarised macrophages.  
4.3 Paper III 
In the paper III, we investigated in vitro chondrogenic potential of surplus chondrocytes from 
14 ACI procedures with the aim of establishing a functional bioassay to predict clinical 
outcomes. Chondrocytes from different donors displayed distinct chondrogenic potential, 
which allowed categorisation of donors into two groups using Bern score. Donors in “Group 
A” and “Group B” represented spheroids with good and bad cartilage-like characteristics, 
respectively. Lysholm score 65 at two-year follow-up was used as the cut-off value to group 
patients into clinical success and failure. When comparing Lysholm scores at two-year follow-
up after ACI surgery with donor-matched in vitro chondrogenic capacity of chondrocytes, we 
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could not find a significant correlation between in vitro chondrogenic potentials and clinical 
outcomes. We also evaluated a number of previously reported markers in our studied material 
to predict the clinical outcomes and chondrogenic potentials. We observed significant 
upregulation of CD166 surface expression in clinical success group compared to failure group. 
When investigating surface expression in chondrogenic groups, the CD106 marker was 
significantly high in the chondrogenic group B.  
In gene expression analysis, we found significant upregulation of ITGA1 (CD49a) and ITGB1 
(CD29) in the good chondrogenic group, whereas TGFβRIII was significantly downregulated 
in this group. Relative expression of COMP was significantly higher in the clinical failure group 
compared to clinical success group. Additionally, we performed an unbiased approach to look 
for predictive biomarkers in both chondrogenic and clinical groups using quantitative 6-plex 
TMT proteomics. We identified 2113 and 2034 proteins from chondrocytes extracts in the 
chondrogenic and clinical groups, respectively. Seven proteins were significantly 
downregulated (FDR = 0.05) in the bad chondrogenic group B compared to group A. 
Importantly, prolyl-4-hydroxylase 1 (P4HA1), an enzyme that plays a pivotal role in triple helix 
formation of collagens, was the only differentially expressed protein in the chondrogenic groups 
when FDR set at 0.01. This finding was also validated using western blots. We did not observe 
any differentially expressed proteins when comparing clinical groups.  
5 General discussion 
Articular cartilage lesions in synovial joints result in pain and discomfort, which may promote 
degeneration of cartilage and prolong sufferings due to the poor healing capacity of this 
specialised tissue. Several treatment strategies such as microfracture, mosaicplasty, ACI, 
transplantation of chondrocytes or stem cells with or without scaffolds, have been used to treat 
localised cartilage defects [59]. The ultimate goal of these methods is to develop durable 
articular cartilage. However, in most instances, the repair tissue results in fibrocartilage 
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formation or a mix of hyaline and fibrocartilage development [35, 49, 57, 252]. None of these 
treatment procedures has been proven superior to each other [253]. Additionally, these 
treatment procedures are not useful in advanced osteoarthritis [38, 43, 52, 53]. The management 
of cartilage lesions represents a weighty clinical challenge worldwide for younger patients who 
may require joint replacement procedure. This is because of the increasing prevalence of this 
debilitating disease due to prolongation of life expectancy and the absence of effective 
treatment strategies for articular cartilage regeneration. Therefore, it is of ample importance to 
developing new treatment procedures that can circumvent the problems and limitations 
associated with currently used methods. In this thesis, we tried to enrich our knowledge around 
cartilage neotissue formation by investigating different cell sources, gather new knowledge 
about cell-based biomarkers for chondrogenesis and clinical outcomes, and to explore the anti-
inflammatory and immunomodulatory potential of supernatants of MSCs obtained from 
different tissues. The role of transplanted MSCs as “drug stores” and signalling agents that 
promote healing by modulating the microenvironment rather than forming new tissue is gaining 
momentum in recent years.   
Articular cartilage repair using culture-expanded autologous chondrocytes has been adapted in 
the clinics during the last decades since its first intervention in the 90s [34, 44, 45]. One of the 
major limitations of this technique is that culture-expanded cells become dedifferentiated and 
loss of phenotypic traits [48, 119]. To ameliorate this characteristic of chondrocytes, MSCs 
have been introduced as an alternative cell source due to their cartilage tissue regeneration 
potential [126, 254]. Still, there is no consensus on the optimal cell source for cartilage repair. 
Stromal cells bone marrow and adipose tissue, in addition to chondrocytes, are the most widely 
used cell sources in both clinical and preclinical settings. Importantly, the previous study 
showed no differences in clinical outcomes in patients treated with ACs and BMSCs [190]. 
Another study comparing ACs and SMSCs demonstrated that SMSCs improved clinical 
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outcomes in treated patients compared to ACs [77]. However, autologous MSCs have several 
limitations. One of the difficulties involves donor site morbidity and limited availability of 
donor tissue from some patients, for example, autologous bone marrow-MSCs from 
myelofibrosis patients. It has also been demonstrated that autologous MSCs harvested from 
elderly donors have decreased regenerative potential and biological activities [78, 79, 255, 256]. 
In addition, systemic diseases, such as rheumatoid arthritis, diabetes, and systemic lupus 
erythematosus, have been shown to alter the intrinsic functional properties of autologous MSCs 
[257-259]. UCSCs overcome the above-mentioned constraints. This primitive cell type can be 
stored and readily available for use in the clinics. In addition, UCSCs have also been 
demonstrated to exert immunosuppressive effects [260, 261]. These features make this cell 
source an attractive candidate for allogeneic transplantation. However, it has been studied in 
the context of cartilage tissue engineering with divergent outcomes [84, 87, 93]. In this study, 
we investigated in vitro chondrogenic potential of MSCs harvested from the umbilical cord and 
compared the outcomes with other cells harvested from the adult knee joint.  
We used histological scoring (Bern score) of Alcian blue stained spheroids to evaluate the 
chondrogenic potential of each cell types. This semi-quantitative scoring method has been 
routinely used in the field of cartilage tissue engineering and validated for GAG measurements 
in pellet cultures [235, 236]. We included six most commonly featured combinations of growth 
factors to investigate the chondrogenic potential. Each cell type displayed distinct 
chondrogenesis in the presence of different growth factors. UCSCs showed poor chondrogenic 
potential in all six combinations of growth factors. Only a few comparative studies reported 
similar findings and argued about their differentiation potential towards chondrogenic lineages 
[93, 95]. We performed cartilage signature gene expression analysis, GAG analysis, TEM and 
Collagen type I and II immunostaining to validate this finding and compared with ACs, which 
is considered the “gold standard.” All these analyses revealed the poor chondrogenic capacity 
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of UCSCs. On the other hand, HFPSCs and SMSCs underwent better chondrogenesis in the 
presence of TGF-β3 and TGF-β1, respectively, in combination with BMP-2 and 
dexamethasone. Other studies have also been reported similar findings [132, 262]. We observed 
significantly higher expression of COL10A and VCAN in spheroids from HFPSCs. These 
markers were reported to associate with hypertrophy and bone formation [263, 264]. The use 
of PTHrP in the chondrogenic medium was reported to inhibit these characteristics [151]. 
It has been reported that hypoxia maintained undifferentiated phenotype of UCSCs [265]. To 
answer this question, we investigated the expression of SRTF genes including OCT4A, 
NANOG, and SOX2 in our studied material. The results from this analysis indicated that 
hypoxia was not involved in restraining chondrogenic potential of UCSCs. Low receptor 
expression has been demonstrated to affect the chondrogenic potential of MSCs using BMP-2 
stimulation [266]. However, we did not see any differences in UCSCs while comparing BMP-
2 and BMP-7 stimulation. Importantly, when we looked at gene expression of receptors from 
TGF-β superfamily, we observed both TGFβRII and TGFβRIII were significantly 
downregulated in UCSCs. TGFβRII binds with ligands and activates TGFβRI, which mediates 
downstream SMAD signalling and chondrogenesis [145, 146]. These results indicate that 
UCSCs are not a suitable source for cartilage neotissue formation. It could be due to their low 
expression of TGF-β receptor type II. Therefore, the use of TGF-β based stimulation for 
chondrogenesis of these cell types might become redundant. A complementary study 
investigating specific receptor type and their signalling pathway could provide a mechanistic 
insight regarding the poor chondrogenesis of UCSCs.  
The mechanisms used by MSCs in tissue regeneration are not yet well established. Earlier it 
was believed that MSCs engraft to the injured tissue and promote tissue regeneration [159]. 
Newer studies, on the other hand, have demonstrated paracrine signalling and secretory 
bioactive molecules that promote tissue repair rather than direct cell engraftment and 
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differentiation [163, 164, 267]. No human study has investigated quality and fate of implanted 
cells due to ethical constraints. A recent clinical trial demonstrated that allogeneic BMSCs 
orchestrated cartilage tissue repair through trophic mediation rather than differentiating into the 
new host tissue [167]. Based on the new way of understanding the mechanism of MSCs, we 
investigated secreted trophic factors, and paracrine signalling of MSCs harvested from 
HFPSCs, SMSCs, and UCSCs, and we compared these factors with culture-expanded 
chondrocytes.   
Results from both LC-MS/MS and multiplex protein array indicated that UCSCs constitutively 
release higher levels of soluble bioactive molecules promoting anti-inflammatory and anabolic 
activities compared to mesenchymal cells harvested from adult tissues. These molecules 
include TGF-β1, PDGFD, and PGE2 that were detected at high concentration in the 
supernatants of UCSCs; whereas MMPs, IL-17, and complement factors were detected at very 
low concentration. TGF-β1 is a master regulator of chondrogenesis and has been shown to 
ameliorate OA pathogenesis [142, 268]. Like TGF-β1, it has been shown that PGE2 secreted 
from MSCs, mediated inhibition of arthritic inflammation in an IL-6 dependent manner [269]. 
On the other hand, MMPs are key catabolic factors that are involved in ECM homeostasis and 
proteolytic processes [270]. Mechanistically, IL-17 has been reported to inhibit chondrogenesis 
and promote MMPs in chondrocytes [271, 272]. Despite the omnidirectional role of soluble 
bioactive molecules, our observations from the global expression of released factors in culture 
media indicated that UCSCs displayed a favourable secretory protein profile for tissue repair.  
We also performed functional assays to investigate immunomodulatory effects of conditioned 
medium from different cell types on activated immune cells. We observed that supernatants 
from UCSCs had superior effect in blocking lymphocytes proliferation and the M1 polarisation 
of macrophages. Articular chondrocytes, bone marrow, and adipose tissue stromal cells are the 
most commonly used sources for cartilage repair [180]. Importantly, there is no consensus on 
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which cell source is beneficial in the context of modulating inflammation. We found only one 
clinical study that demonstrated the superior healing power of SMSCs over ACs [77]. In line 
with our study, MSCs from cords have been shown to exert superior immunomodulatory effects 
compared to BMSCs [273]. Similar findings have also been documented in animal models [174, 
274]. However, MSCs have been shown to be differentially stimulated upon exposure to 
different stages of disease [170]. Therefore, the findings from this study need to be validated in 
suitable animal models. Collectively, these results displayed better secretome profiles of 
UCSCs compared to MSCs from the adult origin. Due to their intrinsic immunosuppressive 
functions, UCSCs might be used as an adjuvant therapy in combination with chondrocytes to 
promote cartilage regeneration as shown using allogeneic BMSCs [167, 194].  
Biological repair of articular cartilage lesions using ACI can not only promote cartilage 
regeneration but also prevent secondary OA progression [275] and delay the need for total knee 
arthroplasty. Although successful clinical outcomes of ACI have been reported for up to 20 
years [46, 276]; their long-term failure rate range between 20-40 % [47, 51]. This indicates that 
the ACI procedure is only beneficial to a sub-group of patients. Such findings have led 
researchers to look for predictive tools that can identify patients who are likely to obtain an 
optimal outcome from ACI procedure. Some risk factors such as age, sex, and previous surgery 
to the index knee have been identified to predict clinical outcome [198, 199]. Others have 
proposed putative biomarkers in synovial fluid or serum to predict the clinical outcome of ACI 
[202, 204]. Additionally, the quality of cells and their influence on cartilage repair have also 
been investigated to identify potential biomarkers [207, 218]. Nonetheless, direct comparison 
of in vitro chondrogenic potency of patient-matched cells with clinical outcomes has not been 
made hitherto. From a cohort of 14 ACI patients, we observed distinct chondrogenic abilities 
from chondrocytes of different donors. Based on this finding, we investigated whether in vitro 
chondrogenic potential can be used as a functional bioassay to predict the clinical outcomes of 
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ACI. However, we found no correlations between two-year clinical outcome after ACI surgery 
and in vitro chondrogenic abilities of culture-expanded chondrocytes. It is uncertain to what 
degree implanted cells participate in rebuilding damaged tissue. Results from a few preclinical 
studies demonstrated that the majority of cells in the repaired tissue are of unknown origin [160, 
161]. In patients, on the other hand, it has been reported that the quality of the repaired tissue 
assessed by histology does not always correlate with the clinical outcomes [198, 277].  
A number of biomarkers associated with cell quality and chondrogenic potential have been 
proposed. In our study, molecular biomarkers associated with chondrogenesis had no value as 
predictors of clinical outcomes and vice versa. Stenberg et al. reported similar findings when 
comparing clinical success and failure groups after ACI [215]. Collectively, these results 
indicate that markers associated with chondrogenic abilities have limited or no value in clinical 
settings. It is likely that chondrogenic ability or cell quality is one of many other factors that 
affect clinical outcomes. Probably, we need to use a sophisticated approach by combining 
biomarkers from patients’ clinical parameters, synovial fluid, and cell quality to predict the 
clinical outcomes for ACI procedure. However, one of the limitations of this study was small 
sample size which is because of the discontinuation of ACI procedure at the University Hospital 
of Northern Norway. Since there was no correlation between in vitro chondrogenic potential 
and clinical outcomes, therefore, the use of an additional parameter, such as magnetic resonance 
observation of cartilage repair tissue (MOCART) score would be interesting. It would provide 
a probable link if there exists any between in vitro cell quality and the structural quality of the 
repaired tissue. 
In addition, when we investigated protein expression in clinical success and failure groups. 
From the over 2100 proteins identified in cell extracts, not a single protein was differentially 
expressed at FDR = 0.05. In chondrogenic groups, on the other hand, we found just seven 
differentially expressed proteins including P4HA1, P4HA2, and P4HB at FDR = 0.05. These 
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proteins are involved in biosynthesis and triple helix formation of collagen. In line with our 
study, upregulation of P4HB has been reported in chondrogenically differentiated human 
BMSCs [219]. However, only P4HA1 was significantly upregulated in the good chondrogenic 
group at FDR = 0.01, which was also validated by western blot. This finding indicates that 
P4HA1 could represent a true biomarker to distinguish chondrogenic population from the 
culture-expanded chondrocytes. This potential new tool could help to improve the scaffold-free 
neotissue approach known as chondrosphere® for cartilage repair.  
6 Conclusion and implications 
In the first paper, we demonstrated poor chondrogenic ability of human UCSCs compared to 
cells harvested from the adult joint. We performed different approaches and quantitative 
measurements; however, we were not able to induce chondrogenesis from UCSCs. On the other 
hand, ACs, HFPSCs, and SMSCs underwent good chondrogenesis by pellet cultures. UCSCs 
might not be a suitable source for generation of tissue-engineered cartilage. In an attempt to 
find an explanation, we investigated receptor expression of TGF-β receptor family. We 
observed significant downregulation of TGF-β receptor type II before inducing chondrogenesis 
in UCSCs. This suggests that use of TGF-β based stimulation in our studied materials could be 
redundant to induce chondrogenesis of UCSCs.    
In the second paper, we demonstrated that UCSCs display more favourable secretory protein 
profiles compared to cells harvested from adult joints. Additionally, our data also showed 
superior immunosuppressive effects of UCSCs. Although these cells displayed poor cartilage 
tissue forming ability, findings from paper II suggest that considering the pro-anabolic and 
immunomodulatory potential of UCSCs, this cell source can still be considered as an adjuvant 
therapy in combination with chondrocytes to modulate tissue microenvironment.  
In the third paper, we explored the in vitro chondrogenic capacity of patient-matched 
chondrocytes from ACI procedures as a functional bioassay to predict clinical outcomes. 
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However, we found no correlations between donor-matched in vitro chondrogenesis and short-
term (2 years) clinical outcomes. We also argued on the limitations of using cell-based markers 
and the chondrogenic potential as predictors of clinical outcomes. Additionally, we found prolyl 
hydroxylase enzymes as a potential biomarker that could predict in vitro chondrogenic ability 
of culture-expanded chondrocytes. Further analysis of these markers in chondrocytes 
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